Acumen Pharmaceuticals, Inc. (ABOS) Institutional Ownership

Ownership Summary

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) showed up in the 13F filings of 71 institutional investors as of December 2025.

• These investors collectively held 61.8% of Acumen Pharmaceuticals's outstanding shares in December 2025, up from 60.6% in September 2025.
• Their total shares held in ABOS increased 2.38% from the prior quarter, while the number of investors in Acumen Pharmaceuticals decreased 10.13% year over year.
• Of these 71 funds, 26 grew their exposure to Acumen Pharmaceuticals, 23 cut back, and 22 maintained positions.
• Institutional investors collectively held 37.42Mn shares in Acumen Pharmaceuticals as of December 2025, up by 868.58K shares quarter on quarter, and down 5.54Mn shares year over year.
• RA CAPITAL MANAGEMENT, L.P. is the top holder of Acumen Pharmaceuticals as of December 31, 2025, with 20.99Mn shares representing 34.66% of outstanding stock.
• The biggest buyers of Acumen Pharmaceuticals for the quarter ending December 2025 included RA CAPITAL MANAGEMENT, L.P. (6.06Mn), Alyeska Investment Group, L.P. (1.52Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.51Mn), Ikarian Capital, LLC (799.48K), TWO SIGMA INVESTMENTS, LP (387.59K).
• The largest sellers of Acumen Pharmaceuticals for the quarter ending December 2025 were Laurion Capital Management LP (1.21Mn), FMR LLC (870.15K), JANE STREET GROUP, LLC (52.46K), Goldman Sachs Group Inc (29.02K), Morgan Stanley (22.32K).
• Acumen Pharmaceuticals's 10 largest shareholders as of December 2025 include RA CAPITAL MANAGEMENT, L.P. (20.99Mn), Sands Capital Alternatives, LLC (3.72Mn), Alyeska Investment Group, L.P. (2.45Mn), Franklin Resources Inc (2.31Mn), ADAR1 Capital Management, LLC (2.16Mn), Knollwood Investment Advisory, LLC (1.63Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.51Mn), FMR LLC (1.16Mn), Ikarian Capital, LLC (1.05Mn), Hudson Bay Capital Management LP (968.94K) per Business Quant data.